Back to Search
Start Over
Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant.
- Source :
-
Vaccine [Vaccine] 2006 Mar 15; Vol. 24 (12), pp. 2049-56. Date of Electronic Publication: 2005 Nov 28. - Publication Year :
- 2006
-
Abstract
- A major goal of HIV-1 vaccine development is the induction of mucosal immune responses able to stop or reduce viral infection directly at the portal of entry. We established a heterologous prime/boost vaccination protocol based on intradermal priming with the HIV-1 Tat protein and intranasal boosting with the Tat protein co-administered with the mucosal adjuvant MALP-2. Strong Tat-specific humoral responses were elicited in vaccinated mice at both systemic and mucosal levels. The cellular responses were characterized by a Th1 dominant helper pattern. The heterologous prime/boost regimen was also able to induce Tat-specific CTL, which were absent in animals receiving the homologous prime boost scheme. Thus, the heterologous prime/boost protocol was the only regimen able to evoke both CTL and sIgA responses. This suggests that a similar approach can be exploited to develop multi-component vaccines against HIV-1 infections able to induce both systemic and mucosal immune responses.
- Subjects :
- AIDS Vaccines immunology
Adjuvants, Immunologic
Animals
Cell Culture Techniques
Gene Products, tat administration & dosage
Gene Products, tat immunology
HIV Antibodies blood
HIV-1 immunology
Lipopeptides
Mice
Mice, Inbred BALB C
Oligopeptides administration & dosage
Vaccination
Vaccines, Synthetic immunology
tat Gene Products, Human Immunodeficiency Virus
AIDS Vaccines administration & dosage
HIV Antibodies biosynthesis
HIV-1 chemistry
Immunity, Mucosal immunology
Oligopeptides immunology
Subjects
Details
- Language :
- English
- ISSN :
- 0264-410X
- Volume :
- 24
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Vaccine
- Publication Type :
- Academic Journal
- Accession number :
- 16406225
- Full Text :
- https://doi.org/10.1016/j.vaccine.2005.11.025